Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug
Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.
Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.